These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 3393779)

  • 21. Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
    Markman M; Spriggs D; Burger RA; Carson LF; Lentz SS; Gallion H
    Gynecol Oncol; 2001 Mar; 80(3):359-63. PubMed ID: 11263932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
    J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
    Aeschlimann C; Küpfer A; Schefer H; Cerny T
    Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
    J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survey of chemotherapy of metastatic renal cancer.
    Kühböck J
    Semin Surg Oncol; 1988; 4(2):87-90. PubMed ID: 3293155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
    Escudier B; Droz JP; Rolland F; Terrier-Lacombe MJ; Gravis G; Beuzeboc P; Chauvet B; Chevreau C; Eymard JC; Lesimple T; Merrouche Y; Oudard S; Priou F; Guillemare C; Gourgou S; Culine S;
    J Urol; 2002 Sep; 168(3):959-61. PubMed ID: 12187199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma.
    Rashid MH; Welsh CT; Bissada NK; Chaudhary UB
    Am J Clin Oncol; 2005 Feb; 28(1):107-8. PubMed ID: 15685046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.
    Heim ME; Fiene R; Schick E; Wolpert E; Queisser W
    J Cancer Res Clin Oncol; 1981; 100(1):113-6. PubMed ID: 7240342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885.
    Chang AY; Tu ZN; Bryan GT; Kirkwood JM; Oken MM; Trump DL
    Invest New Drugs; 1994; 12(2):151-3. PubMed ID: 7860234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary toxicity of deferoxamine in children with advanced cancer.
    Weitman SD; Buchanan GR; Kamen BA
    J Natl Cancer Inst; 1991 Dec; 83(24):1834-5. PubMed ID: 1744928
    [No Abstract]   [Full Text] [Related]  

  • 33. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.
    Amato RJ; Perez C; Pagliaro L
    Invest New Drugs; 2002 Nov; 20(4):413-7. PubMed ID: 12448659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in ifosfamide chemotherapy. Proceedings of a symposium. November 4-5, 1989, Key Biscayne, FL.
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):1-79. PubMed ID: 2333523
    [No Abstract]   [Full Text] [Related]  

  • 35. Rationale for immunotherapy of renal cell carcinoma.
    Heicappell R; Ackermann R
    Urol Res; 1990; 18(6):357-72. PubMed ID: 2100410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Dechant KL; Brogden RN; Pilkington T; Faulds D
    Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ifosfamide chemotherapy of metastatic renal cell cancer.
    Bodrogi I; Baki M; Sinkovics I; Eckhardt S
    Semin Surg Oncol; 1988; 4(2):95-6. PubMed ID: 3393779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.
    Droz JP; Theodore C; Ghosn M; Lupera H; Piot G; De Forges A; Klink M; Rouesse J; Amiel JL
    Semin Surg Oncol; 1988; 4(2):97-9. PubMed ID: 3393780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
    Fosså SD; Talle K
    Cancer Treat Rep; 1980; 64(10-11):1103-8. PubMed ID: 6780190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.